Szczecin

• Evaluation of frequency occurrence persistent pulmonary hypertension of newborns treated by salbutamol Ended
  2024-515216-46-00 11 2021-11-15 Breathing disorders as a cause of neonatal respiratory failure
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended
  2024-517389-40-00 4 2021-10-06 acute lymphoblastic leukemia
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended
  2023-509741-12-00 4 2021-09-23 Ulcerative Colitis
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 5 2021-09-23 Neovascular age-related macular degeneration (wet AMD)
• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 5 2021-04-29 Severe and inadequately controlled asthma
• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended
  2024-512837-34-00 5 2020-10-14 Episodic and Chronic Migraine
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended
  2023-507303-55-00 4 2020-09-30 Alzheimer Disease
• Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended
  2023-509801-59-00 5 2020-07-09 Alopecia areata
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef … Ended
  2023-507897-42-00 4 2020-05-12 Prevention of oesophageal strictures in adult patients after endoscopi
• Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended
  2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
• A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended
  2023-506829-11-00 5 2019-05-29 Growth Hormone Deficiency in children
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 5 2018-09-27 Moderately to Severely Active Crohn's Disease
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and … Ended
  2024-512417-41-00 5 Osteoporosis

Showing 313–335 of 335 trials